FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2802207314> ?p ?o ?g. }

• W2802207314 endingPage "20" @default.
• W2802207314 startingPage "10" @default.
• W2802207314 abstract "In the 1980s the importance of HER2 signalling to the aberrant behaviour of a subset of breast cancer cells was recognized for the first time and, consequently, a hitherto unknown subtype of breast cancer - HER2-positive (HER2+) breast cancer was identified. The development of the anti-HER2 class of drugs, first with trastuzumab, followed closely by lapatinib, pertuzumab, and T-DM1, has improved outcomes dramatically. Nevertheless, metastatic HER2+ breast cancer remains an incurable disease and new therapeutic options are needed. Additionally, the rapid changes in treatment standards 5 years ago have left unanswered numerous questions, including the real-life benefit of pertuzumab and T-DM1, since both the CLEOPATRA and EMILIA trials were conducted in populations that no longer exist in practice and, moreover, on the role of endocrine therapy in HER2+ disease. Furthermore, despite significant research efforts, including translational efforts and new imaging techniques, no predictive biomarkers have been clinically validated and therefore a more refined approach to treatment tailoring remains beyond our reach. Finally, a better understanding of resistance to currently existing anti-HER2 agents and of the role played by the microenvironment (e.g. immune system) and of interconnected signalling pathways (e.g. PI3K-mTOR-AKT) is at the core of clinical trials exploring new drugs and new regimens. These include the combination of anti-HER2 agents and anti-PD-1/PDL-1, PI3K inhibitors and CDK 4/6 inhibitors, as well as a host of new panHER inhibitors, drug antibody conjugates and anti-HER antibodies, which may, in coming years further push the boundaries of what we can do for our patients." @default.
• W2802207314 created "2018-05-17" @default.
• W2802207314 creator A5004669734 @default.
• W2802207314 creator A5015067084 @default.
• W2802207314 creator A5055921564 @default.
• W2802207314 creator A5070557420 @default.
• W2802207314 creator A5087380706 @default.
• W2802207314 date "2018-06-01" @default.
• W2802207314 modified "2023-10-18" @default.
• W2802207314 title "Treatment of advanced HER2-positive breast cancer: 2018 and beyond" @default.
• W2802207314 cites W1968863785 @default.
• W2802207314 cites W1983981014 @default.
• W2802207314 cites W1988737162 @default.
• W2802207314 cites W2005895632 @default.
• W2802207314 cites W2006710185 @default.
• W2802207314 cites W2009200158 @default.
• W2802207314 cites W2017307891 @default.
• W2802207314 cites W2029166421 @default.
• W2802207314 cites W2052895802 @default.
• W2802207314 cites W2053003998 @default.
• W2802207314 cites W2064823103 @default.
• W2802207314 cites W2066471812 @default.
• W2802207314 cites W2076549720 @default.
• W2802207314 cites W2078825674 @default.
• W2802207314 cites W2085178844 @default.
• W2802207314 cites W2088882392 @default.
• W2802207314 cites W2095156669 @default.
• W2802207314 cites W2097698108 @default.
• W2802207314 cites W2101824720 @default.
• W2802207314 cites W2101979288 @default.
• W2802207314 cites W2103808574 @default.
• W2802207314 cites W2107060788 @default.
• W2802207314 cites W2110444464 @default.
• W2802207314 cites W2115175878 @default.
• W2802207314 cites W2116056409 @default.
• W2802207314 cites W2117692326 @default.
• W2802207314 cites W2117793816 @default.
• W2802207314 cites W2118393374 @default.
• W2802207314 cites W2120627364 @default.
• W2802207314 cites W2124845354 @default.
• W2802207314 cites W2132537022 @default.
• W2802207314 cites W2132628497 @default.
• W2802207314 cites W2134031795 @default.
• W2802207314 cites W2137228442 @default.
• W2802207314 cites W2140055441 @default.
• W2802207314 cites W2141393790 @default.
• W2802207314 cites W2159296014 @default.
• W2802207314 cites W2159967578 @default.
• W2802207314 cites W2163750567 @default.
• W2802207314 cites W2165238581 @default.
• W2802207314 cites W2166199281 @default.
• W2802207314 cites W2175378170 @default.
• W2802207314 cites W2198899045 @default.
• W2802207314 cites W2251611718 @default.
• W2802207314 cites W2267591082 @default.
• W2802207314 cites W2281842333 @default.
• W2802207314 cites W2285800240 @default.
• W2802207314 cites W2285875128 @default.
• W2802207314 cites W2286693725 @default.
• W2802207314 cites W2299045691 @default.
• W2802207314 cites W2306345333 @default.
• W2802207314 cites W2327195911 @default.
• W2802207314 cites W2338611117 @default.
• W2802207314 cites W2342106271 @default.
• W2802207314 cites W2404900873 @default.
• W2802207314 cites W2418561090 @default.
• W2802207314 cites W2419312609 @default.
• W2802207314 cites W2475548831 @default.
• W2802207314 cites W2512440162 @default.
• W2802207314 cites W2518718875 @default.
• W2802207314 cites W2546973056 @default.
• W2802207314 cites W2551315898 @default.
• W2802207314 cites W2559858344 @default.
• W2802207314 cites W2571057012 @default.
• W2802207314 cites W2580983429 @default.
• W2802207314 cites W2582248920 @default.
• W2802207314 cites W2586710091 @default.
• W2802207314 cites W2589036504 @default.
• W2802207314 cites W2589844326 @default.
• W2802207314 cites W2591481727 @default.
• W2802207314 cites W2594523589 @default.
• W2802207314 cites W2594677053 @default.
• W2802207314 cites W2597045666 @default.
• W2802207314 cites W2597786088 @default.
• W2802207314 cites W2609953159 @default.
• W2802207314 cites W2613098450 @default.
• W2802207314 cites W2614773797 @default.
• W2802207314 cites W2616596696 @default.
• W2802207314 cites W2619710211 @default.
• W2802207314 cites W2619858681 @default.
• W2802207314 cites W2624337602 @default.
• W2802207314 cites W2624559025 @default.
• W2802207314 cites W2673643310 @default.
• W2802207314 cites W2711538587 @default.
• W2802207314 cites W2726739357 @default.
• W2802207314 cites W2738734482 @default.
• W2802207314 cites W2738923789 @default.
• W2802207314 cites W2741428492 @default.

• next